At a 4.4% yield, AbbVie pays the highest dividend in S&P 500’s entire healthcare sector, and Abbott offers a much more modest yield of 1.6%. Ariad, meanwhile, is not attractive for income-seeking investors, though Loeb has held the stock since the second quarter of last year. Wall Street’s average price target on Ariad represents an upside of more than 40%, though “monkeys” may be best off by considering all three of these biotech stocks in tandem.
Insider Monkey's small-cap strategy returned 25.4% between September 2012 and January 2013 versus 7.4% for the S&P 500 index. Try it now by clicking the link above.